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Abstract 
 Objective: In the modern healthcare system, rapidly expanding costs/complexity, the 
growing myriad of treatment options, and exploding information streams that often do not 
effectively reach the front lines hinder the ability to choose optimal treatment decisions over 
time.  The goal in this paper is to develop a general purpose (non-disease-specific) 
computational/artificial intelligence (AI) framework to address these challenges.  This 
framework serves two potential functions: 1) a simulation environment for exploring various 
healthcare policies, payment methodologies, etc., and 2) the basis for clinical artificial 
intelligence – an AI that can “think like a doctor.”   
Methods: This approach combines Markov decision processes and dynamic decision 
networks to learn from clinical data and develop complex plans via simulation of alternative 
sequential decision paths while capturing the sometimes conflicting, sometimes synergistic 
interactions of various components in the healthcare system.  It can operate in partially 
observable environments (in the case of missing observations or data) by maintaining belief 
states about patient health status and functions as an online agent that plans and re-plans as 
actions are performed and new observations are obtained.  This framework was evaluated using 
real patient data from an electronic health record.   
Results: The results demonstrate the feasibility of this approach; such an AI framework 
easily outperforms the current treatment-as-usual (TAU) case-rate/fee-for-service models of 
healthcare. The cost per unit of outcome change (CPUC) was $189 vs. $497 for AI vs. TAU 
(where lower is considered optimal) – while at the same time the AI approach could obtain a 30-
35% increase in patient outcomes.  Tweaking certain AI model parameters could further enhance 
this advantage, obtaining approximately 50% more improvement (outcome change) for roughly 
half the costs. 
Conclusion:  Given careful design and problem formulation, an AI simulation framework 
can approximate optimal decisions even in complex and uncertain environments.  Future work is 
described that outlines potential lines of research and integration of machine learning algorithms 
for personalized medicine. 
 
Keywords: Markov Decision Process; Dynamic Decision Network; Multi-Agent System; 
Clinical Artificial Intelligence; Medical Decision Making; Chronic Illness  
1. Introduction 
1.1 Problem 
 There are multiple major problems in the functioning and delivery of the modern 
healthcare system – rapidly expanding costs and complexity, the growing myriad of treatment 
options, and exploding information streams that often do not, or at most ineffectively, reach the 
front lines.  Even the answer to the basic healthcare question of “What's wrong with this person” 
often remains elusive in the modern era – let alone clear answers on the most effective treatment 
for an individual or how we achieve lower costs and greater efficiency.  With the expanding use 
of electronic health records (EHRs) and growth of large public biomedical datasets (e.g. 
GenBank, caBig), the area is ripe for applications of computational and artificial intelligence 
(AI) techniques in order to uncover fundamental patterns that can be used to predict optimal 
treatments, minimize side effects, reduce medical errors/costs, and better integrate research and 
practice [1].   
These challenges represent significant opportunities for improvement.  Currently, patients 
receive correct diagnoses and treatment less than 50% of the time (at first pass) [2].  There is 
stark evidence of a 13-17 year gap between research and practice in clinical care [3].  This reality 
suggests that the current methods for moving scientific results into actual clinical practice are 
lacking. Furthermore, evidence-based treatments derived from such research are often out-of-
date by the time they reach widespread use and don’t always account for real-world variation 
that typically impedes effective implementation [4].  At the same time, healthcare costs continue 
to spiral out-of-control, on pace to reach 30% of gross domestic product by 2050 at current 
growth rates [5].  Training a human doctor to understand/memorize all the complexity of modern 
healthcare, even in their specialty domain, is a costly and lengthy process – for instance, training 
a human surgeon now takes on average 10 years or 10,000 hours of intensive involvement [6].  
 
1.2 Goal 
The goal in this paper is to develop a general purpose (non-disease-specific) 
computational/AI framework in an attempt to address these challenges.  Such a framework 
serves two potential functions.  First, it provides a simulation environment for understanding and 
predicting the consequences of various treatment or policy choices.  Such simulation modeling 
can help improve decision-making and the fundamental understanding of the healthcare system 
and clinical process – its elements, their interactions, and the end result – by playing out 
numerous potential scenarios in advance.  Secondly, such a framework can provide the basis for 
clinical artificial intelligence that can deliberate in advance, form contingency plans to cope with 
uncertainty, and adjust to changing information on the fly.  In essence, we are attempting to 
replicate clinician decision-making via simulation.  With careful design and problem 
formulation, we hypothesize that such an AI simulation framework can approximate optimal 
decisions even in complex and uncertain environments, and approach – and perhaps surpass – 
human decision-making performance for certain tasks.  We test this hypothesis using real patient 
data from an EHR. 
Combining autonomous AI with human clinicians may serve as the most effective long-
term path.  Let humans do what they do well, and let machines do what they do well.  In the end, 
we may maximize the potential of both.  Such technology has the potential to function in 
multiple roles: enhanced telemedicine services, automated clinician’s assistants, and next-
generation clinical decision support systems (CDSS) [7,8]. 
 
1.3 Previous work 
In previous work, we have detailed computational approaches for determining optimal 
treatment decisions at single timepoints via the use of data mining/machine learning techniques.  
Initial results of such approaches have achieved success rates of near 80% in predicting optimal 
treatment for individual patients with complex, chronic illness, and hold promise for further 
improvement [7,9].  Predictive algorithms based on such data-driven models are essentially an 
individualized form of practice-based evidence drawn from the live population.  Another term 
for this is “personalized medicine.” 
The ability to adapt specific treatments to fit the characteristics of an individual’s 
disorder transcends the traditional disease model.  Prior work in this area has primarily addressed 
the utility of genetic data to inform individualized care.  However, it is likely that the next 
decade will see the integration of multiple sources of data - genetic, clinical, socio-demographic 
– to build a more complete profile of the individual, their inherited risks, and the 
environmental/behavioral factors associated with disorder and the effective treatment thereof 
[10].  Indeed, we already see the trend of combining clinical and genetic indicators in prediction 
of cancer prognosis as a way of developing cheaper, more effective prognostic tools [11-13]. 
 Such computational approaches can serve as a component of a larger potential framework 
for real-time data-driven clinical decision support, or “adaptive decision support.”  This 
framework can be integrated into an existing clinical workflow, essentially functioning as a form 
of artificial intelligence that “lives” within the clinical system, can “learn” over time, and can 
adapt to the variation seen in the actual real-world population (Figure 1).  The approach is two-
pronged – both developing new knowledge about effective clinical practices as well as 
modifying existing knowledge and evidence-based models to fit real-world settings [7,9]. 
 
Figure 1: Clinical decision-making – flow diagram 
 
A high-level example of information flow during the clinical process through an electronic health record (EHR) across 
time.  Information gleaned at Time 1 can be utilized at Time 2.  Data flows from the front-end (clinical information 
module) to a backend EHR database, which can then be pushed into a data warehouse (DW).  The DW can analyze this 
raw data and then push information or recommendations back to the front-end.  AI algorithms can “live” in this DW and 
integrate into an existing clinical workflow, learning over time. 
 
1.4 Computational approaches to sequential decision making 
 The focus of the current study is to extend the prior work beyond optimizing treatments 
at single decision points in clinical settings.  This paper considers sequential decision processes, 
in which a sequence of interrelated decisions must be made over time, such as those encountered 
in the treatment of chronic disorders.   
At a broad level, modeling of dynamic sequential decision-making in medicine has a long 
and varied history.  Among these modeling techniques are the Markov-based approaches used 
here, originally described in terms of medical decision-making by Beck and Pauker [14].  Other 
approaches utilize dynamic influence diagrams [15] or decision trees [16, 17] to model temporal 
decisions.  An exhaustive review of these approaches is beyond the scope of this article, but a 
general overview of simulation modeling techniques can be found in Stahl 2008 [17].  In all 
cases, the goal is to determine optimal sequences of decisions out to some horizon.  The 
treatment of time – whether it is continuous or discrete, and (if the latter) how time units are 
determined – is a critical aspect in any modeling effort [17], as are the trade-offs between 
solution quality and solution time [15].  Problems can be either finite-horizon or infinite-horizon.  
In either case, utilities/ rewards of various decisions can be undiscounted or discounted, where 
discounting increases the importance of short-term utilities/rewards over long-term ones [18].   
Markov decision processes (MDPs) are one efficient technique for determining such 
optimal sequential decisions (termed a “policy”) in dynamic and uncertain environments [18,19], 
and have been explored in medical decision-making problems in recent years [18,20].  MDPs 
(and their partially observable cousins) directly address many of the challenges faced in clinical 
decision-making [17,18].  Clinicians typically determine the course of treatment considering 
current health status as well as some internal approximation of the outcome of possible future 
treatment decisions. However, the effect of treatment for a given patient is non-deterministic (i.e. 
uncertain), and attempting to predict the effects of a series of treatments over time only 
compounds this uncertainty.  A Markov approach provides a principled, efficient method to 
perform probabilistic inference over time given such non-deterministic action effects.   Other 
complexities (and/or sources of uncertainty) include limited resources, unpredictable patient 
behavior (e.g., lack of medication adherence), and variable treatment response time.  These 
sources of uncertainty can be directly modeled as probabilistic components in a Markov model 
[19].  Additionally, the use of outcome deltas, averse to clinical outcomes themselves, can 
provide a convenient history meta-variable for maintaining the central Markov assumption: that 
the state at time t depends only on the information at time t-1 [17].   Currently, most treatment 
decisions in the medical domain are made via ad-hoc or heuristic approaches, but there is a 
growing body of evidence that such complex treatment decisions are better handled through 
modeling rather than intuition alone [18,21]. 
Partially observable Markov decision processes (POMDPs) extend MDPs by maintaining 
internal belief states about patient status, treatment effect, etc., similar to the cognitive planning 
aspects in a human clinician [22,23].   This is essential for dealing with real-world clinical issues 
of noisy observations and missing data (e.g. no observation at a given timepoint).  By using 
temporal belief states, POMDPs can account for the probabilistic relationship between 
observations and underlying health status over time and reason/predict even when observations 
are missing, while still using existing methods to perform efficient Bayesian inference.  
MDPs/POMDPs can also be designed as online AI agents – determining an optimal policy at 
each timepoint (t), taking an action based on that optimal policy, then re-determining the optimal 
policy at the next timepoint (t+1) based on new information and/or the observed effects of 
performed actions [24,25]. 
A challenge in applying MDP/POMDPs is that they require a data-intensive estimation 
step to generate reasonable transition models – how belief states evolve over time – and 
observation models – how unobserved variables affect observed quantities. Large state/decision 
spaces are also computationally expensive to solve particularly in the partially observable 
setting, and must adhere to specific Markov assumptions that the current timepoint (t) is 
dependent only on the previous timepoint (t-1).  Careful formulation of the problem and state 
space is necessary to handle such issues [17,19]. 
 
1.5 Current work  
There have been many applications in other domains, such as robotics, manufacturing, 
and inventory control [17,19,26].  However, despite such applicability of sequential decision-
making techniques like MDPs to medical decision-making, there have been relatively few 
applications in healthcare [18,19]. 
Here, we outline a MDP/POMDP simulation framework using agents based on clinical 
EHR data drawn from real patients in a chronic care setting.  We attempt to optimize “clinical 
utility” in terms of cost-effectiveness of treatment (utilizing both outcomes and costs) while 
accurately reflecting realistic clinical decision-making.  The focus is on the physician’s (or 
physician agent’s) optimization of treatment decisions over time.  We compare the results of 
these computational approaches with existing treatment-as-usual approaches to test our primary 
hypothesis – whether we can construct a viable AI framework from existing techniques that can 
approach or even surpass human decision-making performance (see Section 1.2).   
The framework is structured as a multi-agent system (MAS) for future potential studies, 
though at the current juncture this aspect is not fully leveraged.  However, combining MDPs and 
MAS opens up many interesting opportunities.  For instance, we can model personalized 
treatment simply by having each patient agent maintain their own individualized transition model 
(see Discussion).  MAS can capture the sometimes synergistic, sometimes conflicting nature of 
various components of such systems and exhibit emergent, complex behavior from simple 
interacting agents [14,27].  For instance, a physician may prescribe a medication, but the patient 
may not adhere to treatment [20].  
 
2. Methods 
2.1 Data 
 Clinical data, including outcomes, treatment information, demographic information, and 
other clinical indicators, was obtained from the electronic health record (EHR) at Centerstone for 
961 patients who participated in the Client-Directed Outcome-Informed (CDOI) pilot study in 
2010 [9], as well as patients who participated in the ongoing evaluation of CDOI post-pilot 
phase.  This sample contained 5,807 patients, primarily consisting of major clinical depression 
diagnoses, with a significant number of patients (~65%) exhibiting co-occurring chronic physical 
disorders including hypertension, diabetes, chronic pain, and cardiovascular disease.   
Centerstone providers in Tennessee and Indiana see over 75,000 distinct patients a year 
across over 130 outpatient clinical sites.  Centerstone has a fully-functional system-wide EHR 
that maintains virtually all relevant patient records. 
 In all simulations, 500 randomly selected patients were used.  All other aspects, 
probabilities, and parameters for modeling were estimated directly from the EHR data (e.g. 
average cost per service, expected values of outcome improvement and deterioration, and 
transition model probabilities).  
In all subsequent simulations, a single physician agent with a caseload of 500 randomly 
selected patients was used.  The framework can handle multiple physician agents (from a 
programming code standpoint, see Section 2.2), but at the present time there are no variable 
behaviors across physicians (e.g. variable attitudes towards outcome significance, where one 
physician pays a lot of attention to outcome observations and another does not).  The physician 
agent must make a treatment decision for each patient at each timepoint over the course of seven 
sessions (plus baseline/intake, max total sessions=8). 
The primary outcome of interest used here is the Outcome Rating Scale (ORS) 
component of the CDOI assessment, which is a validated ultra-brief measure of functioning and 
symptomology for chronic and acute mental disorders, with over a decade of research supporting 
its use in similar settings and populations [28].  The ORS correlates highly with lengthier, 
traditional outcome measures such as OQ-45 and the Quality of Life Scale (QOLS) [29].  The 
ORS has been shown previously to be useful as the basis for machine learning algorithms to 
predict individualized patient treatment response [9]. 
The utility metric, which is used to evaluate the quality of decisions in a model, is cost 
per unit change (CPUC), which measures the cost in dollars it takes to obtain one unit of 
outcome change (delta) on a given outcome [30].  In essence, CPUC is a relative measure of 
cost-effectiveness of treatment, given as a ratio between costs and outcome change.  In this 
study, CPUC was calculated using the change in CDOI-ORS over time (delta) - the delta 
calculation varying dependent on the formulation of the transition model (Section 2.4).  
However, CPUC could be calculated for any disease and/or outcome measure – e.g. blood 
pressure, cancer metastasis stage, hospitalization days, quality-adjusted life years (QALYs).  
Hence, the use of CPUC, rather than directly using outcomes, for utility/rewards in the modeling 
framework is principle to keeping the model general purpose (non-disease-specific).  
 
2.2 Framework overview 
 A general framework overview can be seen in Figure 2, which is further elaborated in 
Sections 2.3-2.5 below.  The agents (shown in double-line borders) encapsulate the 
characteristics and functions of their respective real-life counterparts – e.g. patient agents 
incorporate individual patient-specific data and individualized transition models (see Discussion) 
while physician agents maintain beliefs about patients’ health status and treatment effects and 
have decision-making capabilities.   
 
Figure 2: Framework overview 
  
 
The types of agents are shown in double-line borders.  The other boxes represent various aspects of the model.  The 
general flow is: 1) create patient-specific MDPs/physician agent filters evidence into existing beliefs, 2) recurse through 
MDP search tree to determine optimal action, and 3) perform treatment action and update belief states  
 
 Figure 2 also displays the general algorithm (implemented in Python 2.7, 
www.python.org), where initially patient-specific MDPs are created from the transition models 
and physician agents must incorporate patient-specific evidence/information into existing beliefs 
prior to decision-making at each timepoint.  The decision-making process then recurses down the 
MDP search tree, resulting finally in a determination of an optimal current action and updates to 
patient belief states. 
 The algorithm steps are as follows: 
1) Create patient and physician agents 
2) Create patient-specific MDP 
Then, for each timepoint (if not horizon): 
3) Calculate current outcome delta, physician agent filters evidence 
4) Determine optimal current action via MDP search tree 
5) Perform action and update belief states 
6) If action ≠ not treat, return to step 3 
 
2.3 POMDP decision-making environment 
We model the decision-making environment as a finite-horizon, undiscounted, sequential 
decision-making process in which the state st from the state space S consists of a patient’s health 
status at time t.  At each time step the physician agent makes a decision to treat or stop treatment 
(an action at from the binary action space A={0,1}).  Here time corresponds to the number of 
treatment sessions since the patient’s first visit (typically one session=one week).  The physician 
agent receives rewards/utilities, and is asked to pick actions in order to maximize overall utilities. 
Similar decision-making models were used in [19,31,32].  We can model this decision as a 
dynamic decision network (DDN, a type of dynamic Bayesian network), as seen in Figure 3. 
 
Figure 3: Dynamic decision network (DDN) 
 
A dynamic decision network for clinical decision-making.  a = action (e.g. treatment option), s = state (patient’s actual 
underlying health status), o = observation (patient’s observed status/outcome), c = treatment costs, CPUC = 
utilities/rewards (cost per unit change of some outcome measure).  The subscripts represent time slices (e.g. treatment 
sessions). 
 
Here: 
• s = State (patient’s actual status, not directly observable) 
• o = Observation (patient’s observed status/outcome, can be missing) 
• a = Action (e.g. treatment option, not treat) 
• c = Treatment costs 
• CPUC = Utilities/Rewards (in this case, patient’s CPUC) 
 We are interested in the following: at time t, what is the optimal action (a) to choose?  The 
answer depends on what the agent has observed so far, the beliefs the agent has inferred from 
those observations, and what the agent expects might happen in the future. 
In our current implementation, health status is taken to be the delta value (change over 
time, see Section 2.4) of the CDOI-ORS (∆CDOI), given an observation at time t, but more 
generally state models could represent underlying characteristics of disease, 
clinical/demographic characteristics, and individual genetic predispositions.  States – actual, st, 
and belief states, bt (see below) – are derived by discretizing continuous CDOI delta values into 
five discrete bins: High Deterioration (∆CDOI < −4), Low Deterioration (−4 <= ∆CDOI < −1), 
Flatline/Stable (−1 <= ∆CDOI <= 1), Low Improvement (1 < ∆CDOI <= 4) and High 
Improvement (∆CDOI > 4).  These bins are derived from research-validated clinical 
categorization of significant outcome delta classes for CDOI-ORS, described by Miller et al. 
[28].  This binning is necessary for computational tractability (Section 2.5.1). 
We model the effects of actions on the state using a transition model (TR) that encodes 
the probabilistic effects of various treatment actions: 
 
  (1)  
 
which is assumed stationary (invariant to the time step). 
The physician agent’s performance objective is to maximize the improvement in patient 
health, as measured by the change in CDOI-ORS score at the end of treatment, while minimizing 
cost of treatment (e.g. by stopping treatment when the probability of further improvement is 
low).  These two competing objectives are combined via the cost per unit change (CPUC) metric 
that incorporates both outcome delta (change over time) and treatment costs.  Treatment 
strategies with low CPUC are cost effective (high utility).  An optimal strategy 
*
 that minimizes 
CPUC is given as: 
 
  
(2)  
 
where CPS=cost per service for a given session, CT is a random variable denoting accumulated 
cost at the end of treatment, E indicates expected value (since we are calculating over future 
events), and ∆CDOI(π) is calculated as: 
 
  (3)  
 
where CDOIT is a random variable denoting the CDOI-ORS value at the end of treatment.  The 
expectation is taken over future patient health trajectories up to a finite horizon T, here taken to 
be T=8 treatments (based on the typical average number of sessions amongst Centerstone’s 
outpatient population).  In cases where the CDOI delta <= 0, we rescale the delta values so that 
as a utility metric, given equal costs, delta=0 is effectively one unit worse than delta=1, delta= −1 
is one unit worse than delta=0, and so on.  This is done by adding additional costs to the CPUC 
for delta=1. 
 In all cases, the treatment decision must be based on the belief state rather than the true 
underlying state (which cannot be directly observed) – that is, a strategy  is defined as a map 
from belief states to actions:  : 2
S
 A.  In other words, the physician agent’s reasoning is 
performed in a space of belief states, which are probability distributions over the patient’s health 
status, bt(s)=P(st=s).  For instance, we cannot directly observe a patient’s disease state (e.g. 
diabetes); rather, we take measurements of symptoms (e.g. blood glucose) and attempt to classify 
the patient into some underlying disease or health state.  Furthermore, in approximately 30% of 
our data, the clinician makes a treatment decision when the CDOI-ORS observation is missing 
(i.e. partially observable environment), and the belief state must be inferred from previous belief 
states (see below).  The belief state categories are the same as those described above for the true 
underlying state (High Deterioration, Flatline, etc.)  In future work, we would like to extend the 
system to reason optimally when integrating unobserved health factors based on their 
probabilistic relationship to observed clinical/demographic characteristics, as well as account for 
non-deterministic effects of variable treatment options (see Discussion).   
Unconditional on observations, the next belief state, bt+1, is predicted from the prior belief 
(over all possible prior states) using the following exact equation: 
 
 
 
(4)  
 
By repeated application of this predict operation our system can compute forecasts of the 
patient’s health status into the future.   
Over time, uncertainty of the belief state is reduced by relating the observations that are 
actually seen by the physician to the health status; in other words, when observations are 
available, we utilize them to update the belief states.  In our problem, observations ot are drawn 
from the observation space O = {missing}  CDOI.  In the case of a missing observation, ot = 
{missing}, the belief bt(s) is maintained as is after the observation.  This provides a probabilistic 
observation model, which defines the relationship between the true underlying state and possible 
observations: 
 
  (5)  
 
Upon receiving an observation ot , we find the posterior belief over the patient’s state using the 
update operation, which uses Bayes rule to derive the backward relationship from an observation 
to the state distribution: 
 
 
 
(6)  
 
where Z is a normalization factor equal to the unconditional probability of observing ot.  For all 
patients and their current belief state, the physician agent maintains a continuous-valued estimate 
of CDOI-ORS at the given timepoint by applying a Gaussian model of average treatment effect 
(estimated from the EHR data) to the CDOI-ORS value at the previous timepoint given the 
predicted belief state, bt(s) (e.g. High Improvement).  This continuous-valued CDOI-ORS belief 
can be recalculated as a delta and then re-binned into states for future prediction steps, bt+1(s). 
  
2.4 Estimation of transition models 
The goal of the transition model is to use the history of health status – i.e. outcome delta 
– to predict the probability distribution of future health states on the subsequent time step.  Let ht 
denote the history of observations (o1,…,ot).  We compare three model classes for predicting the 
change in CDOI-ORS from the current to the next step: CDOIt = CDOIt+1− CDOIt.  
1) 0th order – a raw stationary distribution over CDOIt independent of history (i.e. the 
probability of treatment effect, regardless of improvement/deterioration seen thus far): 
P( CDOIt | ht) = P( CDOIt) 
2) 1st order autoregressive (Local) – the distribution over CDOIt depends only on change 
since the previous timepoint (local change): P( CDOIt | ht) = P( CDOIt  | CDOIt−1). 
3) Global average – the distribution over CDOIt depends on the entire patient history (i.e. 
delta since baseline): P( CDOIt | ht) = P( CDOIt  | (CDOIt−CDOI0)). 
 
The 0
th
 order model ignores any effect of the history on future patient outcomes and treats each 
patient like a new average patient regardless of previous observations.  For instance, even if the 
patient has already experienced significant outcome improvement, the 0
th
 order model still 
assumes they are just as likely to improve in the future.  On the other hand, the 1
st
 order local 
model uses the short-term trajectory of prior improvement/deterioration in order to gain 
somewhat better forecasting ability, but only since the most recent timepoint (previous treatment 
session). One potential drawback of this method is that it may be fooled by large and/or spurious 
short-term oscillations in patient outcomes.  The global averaging technique looks at trends over 
a longer time horizon (change since baseline, t=0).  It provides the most comprehensive measure 
but is less sensitive to recent changes, which can be significant for real-world treatment 
decisions.  The global technique also maintains the Markov property required for MDP use by 
capturing the total history of outcome change as a state meta-variable of a given timepoint (see 
Section 2.5.1). In future work, the potential also exists to combine of models of differing orders 
to improve forecasting (e.g. 1
st
 order/local and global deltas). 
For each transition model class, we build a discrete conditional probability table over the 
values of the independent variable using observed statistics from our EHR data (in other words, 
using a separate sample of patients from the EHR, we estimate the transition probabilities needed 
for the model).  To obtain sufficient sample size for the estimation procedure, we bin deltas into 
5 bins (High Deterioration, Low Deterioration, Flatline/Stable, Low improvement, High 
Improvement) based on research-validated clinical categories (see Section 2.3) [28].  For each 
model, we estimated transition probabilities using maximum likelihood from EHR data.  As 
typical for many EHR systems, our dataset only contains CDOI-ORS data for patients to the 
point of treatment termination – i.e., we have no information on patients’ health status after the 
discontinuation of services at Centerstone.  As noted elsewhere, the collection of such “natural 
history” disease data is fraught with many challenges, ethical and otherwise, particularly if such 
untreated conditions pose significant health risks [18].  Hence, we make the coarse 
approximation that untreated individuals, on average, remain roughly constant at CDOIt=0. 
 
2.5 Decision-making strategies 
2.5.1 MDP models 
 To determine optimal actions via the DDN, we compute an optimal treatment strategy via 
exploration of a belief-space search tree (MDP search tree).  Here, we present an online approach 
where the system continually plans, executes, observes, and re-plans the optimal treatment 
strategy from any given timepoint [33]. 
The MDP/POMDP search tree, also sometimes referred to as a stochastic decision tree [34], 
explores the beliefs (b) obtained for all possible actions (a) and probabilistic treatment outcomes 
(observations, o) out into the future (Figure 4).  The tree alternates layers of decision nodes – in 
which the physician agent has a choice of action – and chance nodes – in which the environment 
(including other agents’ actions, non-deterministic treatment effects, and so on) yields uncertain 
changes to the patient health status.  For stop-treatment actions, we also construct terminal 
nodes.  In our case, we end enumerating layers at the finite horizon, T=8 (producing a tree of 
depth 16 in total).  
We then make a backwards pass to compute the optimal decisions at each decision node that 
optimizes CPUC.  The first step in this pass computes the overall CPUC at leaves and terminal 
nodes.  Then, we recursively backup the optimal CPUC for interior nodes all the way to the root.  
The backup operation for chance nodes calculates the expected CPUC over its children (based on 
probabilities), while at decision nodes the backup picks the action that leads to the optimal (in 
this case, minimal) CPUC for its subtree. Once this operation is complete, we can compute the 
optimal strategy.  The optimal strategy is a subtree obtained by keeping all children of chance 
nodes and the single child corresponding to the optimal action at each decision node.  This 
optimal strategy represents a treatment plan given current information.    
 
Figure 4: MDP search tree 
 
 
 
An example MDP search tree for clinical decision-making.  At each layer/time slice, we have a series of decision and 
chance (or terminal) nodes.  Decision nodes represent choices of actions (a, given k possible actions), while chance nodes 
represent possible resulting observations (o, given m possible observations).  Terminal nodes present a utility measure 
(CPUC, represented in dollars).  As none of these actions or observations has occurred yet, we must use probabilistic 
beliefs (b) at each planning step. 
 
Where the various branches, b, can relate to possible observations, o={o1…om}, at the decision 
nodes and actions, a={a1…ak}, at the probabilistic nodes.  Each node contains some utility value 
(here a CPUC value shown in dollars). 
A primary challenge in this approach is exploring the large search tree that can result.  Here, 
we consider 5 observation bins and a “stop treatment” action with no subsequent branches, 
resulting in a search tree with branching factor = 5 and depth = 10 and the generation of over 
100,000 belief states in the worst case.  While tractable for the problem at hand, more complex 
decision problems – such as larger state spaces, action types, or time frames – may require 
approximate solutions [15]. 
 
2.5.2 Comparative models 
 For comparative purposes with the MDP models, we evaluated several simpler decision-
making approaches.  These alternative strategies provide context for interpreting the optimality 
of the MDP results. 
We considered two heuristic policies that represent current healthcare models.  The MDP 
models were constructed only with the 1
st
 order and global transition models described in section 
2.4, as the MDP policy is trivial in the 0
th
 order case because ∆CDOI from t to t+1 is assumed 
independent of prior history.  As such, the 0
th
 order models essentially represent their own 
decision-making approach – henceforth referred to as Raw Effect models, given they consider 
the raw effect of treatment without consideration of outcome change history.  Given its 
optimistic nature, the Raw Effect model results in always treating till the horizon.  The Raw 
Effect model provides an upper baseline, which represents the overly-optimistic scenario of 
assuming treatment always results in patient improvement.  This is, in effect, an approximation 
of the fee-for-service model prevalent in U.S healthcare.  We also considered a Hard Stop 
policy after the third treatment session. The Hard Stop strategy provides a lower baseline, 
simulating the worst-case scenario of simply stopping treatment after some arbitrary timepoint 
without consideration for outcomes (minimizing costs).  This is, in effect, an approximation of 
the case-rate/capacitated model used by many insurance companies.    
Additionally, for the 1
st
 order and global transition models, we consider two simpler 
decision-making approaches (that do consider outcome change history):  
1) Max Improve that assumes the treatment effect of maximum probability always occurs 
for a given action.  This could be considered a “winner-take-all” approach.  
2) Probabilistic models select an action at random, where the action is chosen with 
probability proportional to its likelihood to improve CDOI.  For example, if treatment 
was predicted to improve CDOI with probability 0.9, then the strategy would flip a biased 
coin with probability 0.9 to decide whether to treat. 
 Both of the above models – as well as the Raw Effect model – only consider the probabilities 
of treatment effects for a given action from t to t+1, unlike the MDP approach which can 
calculate utilities of a current action across multiple future timepoints considering possible 
action sequences, treatment effects, and contingency plans.  We consider them here to evaluate 
whether the added complexity of the MDP models results in justifiable performance 
improvement in a healthcare setting. 
 
2.6 Simulation analysis approach 
 For purposes of analysis, simulation experiments were performed across multiple 
permutations of the transition and decision-making models laid out in Sections 2.4 and 2.5 
(henceforth termed constructs). We also considered datasets with and without missing 
observation points. 
Additionally, for the MDP model solved via DDN/search tree, the significance of the 
outcomes was varied via an outcome scaling factor (OSF) that adds in scaled outcome values {0-
1} as an additional component of the utility metric.  The outcomes (current delta) are scaled and 
flipped based on the maximum possible delta for a patient at a given timepoint (deltamax), so that 
higher values (near 1) are worse than lower values (given that we are attempting to minimize 
CPUC): 
 
 
 
(7)  
 
Although any scaling to the range y = {0-1} and flipped so that OSF = 1− y would work.  
Increasing this OSF above 0 increases the added importance of outcomes in the decision-making 
process.  It should be noted – this is "added" influence, because outcomes are already accounted 
for in the basic CPUC reward/utility calculation, even when this factor is set to 0.  When set to 0, 
outcomes are considered equally important as costs. 
For the probabilistic decision-making models (Section 2.5.2), it was necessary to perform 
multiple runs (n=10) of each construct in order to build a statistical sample from which to derive 
mean values for CPUC, outcomes, etc. given these probabilistic models are purely non-
deterministic nature.  For the other decision-making models, this was unnecessary.   
 
3. Results 
3.1 General results 
 Nearly 100 different constructs were evaluated during this study.  For brevity, a sampling 
of the main results is shown in Table 1 (with OSF=0).  In general, the purely probabilistic 
decision-making models performed poorly, and are not shown here.  In all tables, results are 
based averages/percentages across all patients (n=500, see Section 2.1) in each construct 
simulation.  As defined in Section 2.3, the goal here (i.e. optimality) is defined as maximizing 
patient improvement while minimizing treatment costs, which equates to minimizing CPUC.   
Additionally, we would prefer models that maintain reasonably high average final delta values 
and lower standard deviations of delta values. 
 Table 1 shows the results of the Hard Stop (i.e. case rate) and the Raw Effect (i.e. fee-for-
service) decision models first.  It should be noted that – for the former – CPUC is reduced but 
still generally higher than other decision making approaches while outcomes are very low, and 
that – for the latter – outcomes are improved but still generally lower than other decision making 
approaches while CPUC is significantly higher.  In short, neither is optimal. 
Table 1: Model simulation results 
 
1Missing observation  
2Cost per Unit Change 
3Final Delta = change in outcome from baseline to end of treatment 
4Percent of patients receiving maximum number of treatment sessions 
  More sophisticated decision-making models – including the Max Improve and the MDP 
models – performed much more optimally across various constructs.  This included constructs 
with the inclusion of missing observations, which is a realistic challenge faced by any healthcare 
decision-maker.  Generally speaking, the MDP decision-making models outperformed the Max 
Improve models in terms of minimizing CPUC, which was the primary metric of interest.  
However, the MDP approach generally achieved slightly lower outcome deltas, given an OSF=0 
(see section 3.2).  The MDP models did have slightly lower standard deviations for outcome 
deltas across patients except for a few constructs.  In general, the MDP models appeared to be 
more consistent in terms of our definition of optimality.  We can also see that performance 
increases as we move from the 1
st
 order to global transition models. 
These more sophisticated AI decision-making approaches are superior to the 
aforementioned, more simplistic methods that are commonly employed in many healthcare 
payment methodologies (case rate, fee-for-service). An MDP model using a global transition 
model obtained higher outcomes than the Raw Effect (i.e. fee-for-service) model at significantly 
lower CPUC ($189 vs. $497), even in the face of missing observations. 
 It should also be noted that the same values in Table 1 were calculated for the broader 
patient population from Centerstone’s EHR (Centerstone currently operates in a fee-for-service 
payment model).  These “treatment-as-usual” averages were estimated as: CPUC ≈ $540, final 
CDOI-ORS delta ≈ 4.4 ± 9.5, and number of services ≈ 7.1.  These real-world values roughly 
approximate the simulated values for the Raw Effect decision-making model, providing some 
ground validity for the simulation approach. 
 
3.2 MDP variation in outcome scaling factor 
 Since the MDP decision-making approaches consider utilities inherently as part of their 
decision-making approach, they provide additional opportunities for model refinement over other 
approaches, such as the simpler Max Improve model (Section 3.1).  One way to refine the model 
is by adjusting the outcome scaling factor (OSF, Section 2.6).  The results of such adjustment for 
the MDP model (using the global transition model and inclusion of missing observations) are 
shown in Table 2.  Additionally, we ran the same experiment on a variation of the MDP model 
which takes the action with maximum probability (MaxProb) at each chance node, rather than 
the average/expected values (see Section 2.5.1).   This is shown in Table 3. 
Table 2: Outcome scaling – normal MDP 
 
1Missing observation  
2Cost per unit change 
3Final Delta = change in outcome from baseline to end of treatment 
4Percent of patients receiving maximum number of treatment sessions 
 
Table 3: Outcome scaling – MaxProb MDP 
 
1Missing observation  
2Cost per unit change 
3Final Delta = change in outcome from baseline to end of treatment 
4Percent of patients receiving maximum number of treatment sessions 
 
 In Table 2, we can see that adjusting the OSF from 0 to 10 results in increasing outcome 
deltas, as well as increasing CPUC’s.  For the normal MDP, we appear to reach some sort of 
maxima in outcomes around OSF=3 or 4 (which is reflected in the MaxProb MDP below).  After 
this, CPUC continues to rise, but outcome deltas show minimal improvement, even at OSF=10 
and beyond.  Effects on CPUC and outcome delta for both models using OSF ranging [0,15] can 
be seen in Figure 5.     
 We can see in table 3 that the MaxProb MDP show little change across OSF values in 
terms of CPUC or outcome deltas.  This is probably evidence of some global maxima for CPUC 
≈ $220-225 and outcome delta ≈ 6.25-6.35.  Existence of such maxima should be expected given 
the optimization-problem nature of the current framework.  It does suggest that such problems 
may be ripe for application of other optimization techniques for determining model parameters 
such as OSF or action/treatment decision thresholds. 
It should be noted that with OSF=3, the normal MDP obtains CPUC=$224 and outcome 
delta=6.24 in 4.68 treatment sessions.  This appears to be an optimal decision-making model 
across all model formulations given both CPUC and outcome deltas.  It also vastly outperforms 
the aforementioned treatment-as-usual case rate/fee-for-service models (see Section 3.1).  
Essentially, we can obtain approximately 50% more improvement (outcome change) for roughly 
half the costs. 
Figure 5: Outcome scaling effects 
 
The figure shows the effect of different values of the OSF parameter on CPUC (top) and outcome delta, i.e. ∆CDOI 
(bottom), for both the MDP-Normal and MDP-MaxProb Models.  The delta values level off around ≈ 6.25-6.35 while 
CPUC values continue to increase. 
 
4. Discussion 
4.1 Summarization of findings 
 The goal in this paper was to develop a general purpose (non-disease-specific) 
computational/AI framework in attempt to address fundamental healthcare challenges – rising 
costs, sub-optimal quality, difficulty moving research evidence into practice, among others.  This 
framework serves two potential purposes: 
1) A simulation environment for exploring various healthcare policies, payment 
methodologies, etc. 
2) The basis for clinical artificial intelligence – an AI that can “think like a doctor” 
 
This framework utilizes modern computational approaches to learn from clinical data and 
develop complex plans via simulation of numerous, alternative sequential decision paths.  It 
determines optimal actions based on what has been observed so far, the beliefs inferred from 
those observations, and what we expect might happen in the future.  It must do so in a dynamic 
environment as an online agent – which continually plans, observes, and re-plans over time as 
evidence/facts change.  The framework is structured as a multi-agent system, which in future 
work has potential to account for the various conflicting and synergistic interactions of various 
components in the healthcare system. 
The results shown here demonstrate the feasibility of such an approach relative to human 
decision-making performance.  Even in its early stages of development, such an AI framework 
easily outperforms the current treatment-as-usual case-rate/fee-for-service models of healthcare 
(Section 3.1).  Sophisticated modeling approaches utilizing MDPs and DDNs can be further 
tweaked to provide finer control over the utility input of higher outcomes or lower costs (Section 
3.2), providing robust tools for simulation and AI development in the medical domain. 
 
4.2 Future work 
 Despite the work presented here, there are many areas ripe for exploration in this domain.  
We are particularly interested in: 
• Personalized transition models – Integrate machine learning algorithms for optimal 
treatment selection for each patient.  
• Natural history of disease progression – For patients who receive no treatment as an 
action, consider natural history rather than assuming they remain stable. 
• Variable physician agents – Vary behavior/decision-making by physician depending on 
individual physician priors (e.g., variable perceptions of outcome significance). 
• Variable patient agents – Consider variable patient behaviors (e.g. non-adherence to 
treatment, not taking medications, missing appointments). 
• Optimization methods for thresholds – To determine cutoffs of decision points 
between actions, rather than a priori determination via statistical methods.  Agent would 
determine such cut-points “on the fly.” 
• Gaussian noise for activity effects – More realistic modeling of transitions between 
health states.  
• Improved non-deterministic choices – For example, Monte Carlo simulations, rather 
than simply picking the max probability or random number, to determine if this yields 
better results.   
• Better state conceptualization – Consider combined global/local (1st order) delta state 
space to capture both overall patient progress as well as short-term trajectories. 
• Better utility conceptualization – Consider alternative ways to estimate utility of a 
given action (e.g. different methods for weighting costs and outcomes). 
 
For example, given the multi-agent design, the system can be modeled on an individual, 
personalized treatment basis (including genetics), i.e. “personalized medicine” [10].  In previous 
work (see Introduction), we have described using machine learning methods to determine 
optimal treatments at a single timepoint for individual patients [7,9].  Such methods could be 
combined into the sequential decision AI framework described here, simply by incorporating the 
output probabilities of those single-decision point treatment models into the transition models 
used by the sequential decision-making approaches [35].  As such, each patient agent could 
maintain their own individualized transition model, which could then be passed into the 
physician agent at the time of decision-making for each patient.  This is a significant advantage 
over a “one-size-fits-all” approach to healthcare, both in terms of quality as well as efficiency 
[36,37].    
There are, of course, potential ethical issues about how we might use such 
quality/performance information as the basis for clinician reimbursement and/or clinical 
decision-making (e.g. pay-for-performance), but these are broader issues that transcend whether 
we use artificial intelligence techniques or not [38]. 
Other opportunities include considering combinations of global/local (1
st
 order) deltas to 
capture both long-term prognosis as well as short-term trajectories, modeling variable patient 
behaviors (e.g. non-adherence to medications), testing alternative utility metrics, and utilizing 
optimization techniques to determine decision cutoff thresholds between actions on-the-fly. 
 
4.3 Conclusion 
At the end of the day, if we can predict the likely result of a sequence of actions/treatment 
for some time out into the future, we can use that to determine the optimal action right now.  As 
recently pointed out by the Institute of Medicine, does it make sense to continue to have human 
clinicians attempt to estimate the probabilistic effects of multiple actions over time, across 
multitudes of treatment options and variable patient characteristics, in order to derive some 
intuition of the optimal course of action?  Or would we be better served to free them to focus on 
delivery of actual patient care [39]?  The work presented here adds to a growing body of 
evidence that such complex treatment decisions may be better handled through modeling than 
intuition alone [18,21].  Furthermore, the potential exists to extend this framework as a technical 
infrastructure for delivering personalized medicine.  Such an approach presents real opportunities 
to address the fundamental healthcare challenges of our time, and may serve a critical role in 
advancing human performance as well. 
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